Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Systemic Lupus Erythematosus: early-phase trial registry
43 of 100 indexed Systemic Lupus Erythematosus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #136 of 28,707 conditions by registered trial count.
100 US clinical trials · 43 currently recruiting · #136 of 28,707 conditions by registered trial count
Systemic Lupus Erythematosus: 100 US clinical trials tracked, 43 recruiting.
Systemic Lupus Erythematosus is the subject of 100 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 6 of these trials.
Enrollment posture brief
Registry condition systemic-lupus-erythematosus
OPEN 43 | RECR 43% | LATE 21 | EARLY 54 | RANK #136 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Urothelial Carcinoma (43% recruiting · 86 trials)
Systemic Lupus Erythematosus lists 43 open slots (43% of 100 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Systemic Lupus Erythematosus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Systemic Lupus Erythematosus is recruiting above its size-band peers.
43 of 100 indexed trials (43%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Systemic Lupus Erythematosus trials is spread across many organizations.
Bristol-Myers Squibb accounts for 6 of 100 trials (6%). 64 distinct sponsors appear on at least one study for this condition label.
-
Typical Systemic Lupus Erythematosus enrolment sits around 135 participants.
Median target enrolment is 135 among the 100 trials that report a genuine target (sentinel values excluded). 44 of those (44%) plan for fewer than 100 participants.
-
Systemic Lupus Erythematosus research is mostly interventional.
83 interventional and 17 observational studies make up this index (83% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
100 total, page 2 of 2
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Novartis Pharmaceuticals
NCT05624749
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
NCT04895696
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
Galapagos
NCT05856448
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
Novartis Pharmaceuticals
NCT06293365
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
Synthekine
NCT06544330
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
Cugene
NCT05866861
REACH (Restore Energy, Activity Can Help) Lupus Study
Tufts Medical Center
NCT06479213
Centrally Acting ACE Inhibition in SLE
Northwell Health
NCT04486118
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
GlaxoSmithKline
NCT04179032
The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB
Duke University
NCT05818254
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
Sana Biotechnology
NCT06294236
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Century Therapeutics
NCT06255028
Web-based Genetic Research on Lupus
23andMe
NCT02530944
Belimumab Assessment of Safety in SLE
GlaxoSmithKline
NCT01705977
Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
National Institute of Environmental Health Sciences (NIEHS)
NCT00055055
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Human Genome Sciences
NCT00410384
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
MedImmune
NCT01438489
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
Anthera Pharmaceuticals
NCT01305746
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB Biopharma SRL
NCT04294667
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
Eli Lilly and Company
NCT02708095
Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture
National Center for Research Resources (NCRR)
NCT00006134
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Biogen
NCT02847598
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
UCB Pharma
NCT00624351
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
Duke University
NCT03938324
Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology
Brigham and Women's Hospital
NCT05116163
Lupus Atherosclerosis Prevention Study
Johns Hopkins University
NCT00120887
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Oklahoma Medical Research Foundation
NCT00987831
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NYU Langone Health
NCT00000421
Reducing Disparities in Medication Adherence in SLE
Duke University
NCT03738826
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Bristol-Myers Squibb
NCT04186871
GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Genelabs Technologies
NCT00082511
JBT-101 in Systemic Lupus Erythematosus (SLE)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03093402
The Research Registry for Neonatal Lupus
NYU Langone Health
NCT00074373
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
GlaxoSmithKline
NCT01649765
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
Bristol-Myers Squibb
NCT03541564
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
Medical University of South Carolina
NCT02633163
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
GlaxoSmithKline
NCT02119156
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
Daiichi Sankyo
NCT05203692
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Human Genome Sciences Inc., a GSK Company
NCT01597492
FolateScan in Autoimmune Disease
Mayo Clinic
NCT00588393
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
Pfizer
NCT03334851
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
Janssen Research & Development
NCT02609789
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
Kezar Life Sciences
NCT03393013
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
Bristol-Myers Squibb
NCT03254784
The Role of ITGAM in Systemic Lupus Erythematosus
Northwell Health
NCT01230112
CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study
George Washington University
NCT00522002
Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children
Children's Hospital of Philadelphia
NCT01330368
Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
Oklahoma Medical Research Foundation
NCT00594932
Zostavax in Systemic Lupus Erythematosus
Oklahoma Medical Research Foundation
NCT01474720
Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
Children's Hospital Medical Center, Cincinnati
NCT03288324
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 24 |
| Phase 3 | 15 |
| Phase 4 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Systemic Lupus Erythematosus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Systemic Lupus Erythematosus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Systemic Lupus Erythematosus page
100 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Systemic Lupus Erythematosus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Systemic Lupus Erythematosus trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Systemic Lupus Erythematosus condition card totals 100 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.